- Home
- ADUS vs DNLI Comparison
ADUS vs DNLI Comparison
Compare ADUS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUS
- DNLI
- Stock Information
- Founded
- ADUS 1979
- DNLI 2013
- Country
- ADUS United States
- DNLI United States
- Employees
- ADUS N/A
- DNLI N/A
- Industry
- ADUS Medical/Nursing Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADUS Health Care
- DNLI Health Care
- Exchange
- ADUS Nasdaq
- DNLI Nasdaq
- Market Cap
- ADUS 2.1B
- DNLI 2.1B
- IPO Year
- ADUS 2009
- DNLI 2017
- Fundamental
- Price
- ADUS $108.97
- DNLI $13.16
- Analyst Decision
- ADUS Buy
- DNLI Strong Buy
- Analyst Count
- ADUS 12
- DNLI 16
- Target Price
- ADUS $140.58
- DNLI $33.62
- AVG Volume (30 Days)
- ADUS 116.7K
- DNLI 2.0M
- Earning Date
- ADUS 11-03-2025
- DNLI 11-05-2025
- Dividend Yield
- ADUS N/A
- DNLI N/A
- EPS Growth
- ADUS 7.74
- DNLI N/A
- EPS
- ADUS 4.52
- DNLI N/A
- Revenue
- ADUS $1,274,082,000.00
- DNLI N/A
- Revenue This Year
- ADUS $24.29
- DNLI N/A
- Revenue Next Year
- ADUS $6.83
- DNLI $95,463.19
- P/E Ratio
- ADUS $24.12
- DNLI N/A
- Revenue Growth
- ADUS 14.29
- DNLI N/A
- 52 Week Low
- ADUS $88.96
- DNLI $10.57
- 52 Week High
- ADUS $136.72
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ADUS 42.04
- DNLI 33.82
- Support Level
- ADUS $110.05
- DNLI $14.63
- Resistance Level
- ADUS $115.82
- DNLI $15.69
- Average True Range (ATR)
- ADUS 3.03
- DNLI 0.74
- MACD
- ADUS -0.70
- DNLI -0.23
- Stochastic Oscillator
- ADUS 6.98
- DNLI 0.98
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.